Elucidation and pharmacological targeting of novel molecular drivers of follicular lymphoma progression

Cancer Research

Volumn 76, Issue 3, 2016, Pages 664-674

  Bisikirska, Brygida ^a   Bansal, Mukesh ^a   Shen, Yao ^a   Teruya Feldstein, Julie ^b,c   Chaganti, Raju ^b   Califano, Andrea ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLEMASTINE; CYTARABINE; ECONAZOLE; PROMAZINE; PROSTAGLANDIN E1; TRANSCRIPTION FACTOR DP1; TROGLITAZONE;

ARTICLE; ATF5 GENE; B LYMPHOCYTE; CANCER GROWTH; CELL VIABILITY; DRUG POTENTIATION; DRUG TARGETING; FOLLICULAR LYMPHOMA; FOXM1 GENE; GENE; GENE SILENCING; GENE TARGETING; GENETIC ALGORITHM; HMGA1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; LETHALITY; MALIGNANT TRANSFORMATION; MOLECULAR GENETICS; NFYB GENE; PRIORITY JOURNAL; RNA INTERFERENCE; TFDP1 GENE; CELL PROLIFERATION; CELL TRANSFORMATION; DISEASE COURSE; DRUG EFFECTS; GENETICS; LYMPHOMA, FOLLICULAR; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; LYMPHOMA, FOLLICULAR; MOLECULAR TARGETED THERAPY;

EID: 84958206046     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0828     Document Type: Article

References (50)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18.
2. Guirguis HR, Cheung MC, Piliotis E, SpanerD, Berinstein NL, Imrie K, et al. Survival of patients with transformed lymphoma in the rituximab era. Ann Hematol 2014;93:1007-14.
3. Vaandrager JW, Schuuring E, Raap T, Philippo K, Kleiverda K, Kluin P. Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes. Genes Chromosomes Cancer 2000;27: 85-94.
4. Limpens J, Stad R, Vos C, de Vlaam C, de Jong D, van Ommen GJ, et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995;85:2528-36.
5. Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007;25:2426-33.
6. Freedman AS. Biology and management of histologic transformation of indolent lymphoma. Hematology Am Soc Hematol Educ Program 2005: 314-20.
7. Goff LK, Neat MJ, Crawley CR, Jones L, Jones E, Lister TA, et al. The use of real-Time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma. Br J Haematol 2000;111:618-25.
8. Berglund M, Enblad G, Thunberg U, Amini RM, Sundstrom C, Roos G, et al. Genomic imbalances during transformation from follicular lymphoma to diffuse large B-cell lymphoma. Mod Pathol 2007;20:63-75.
9. Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB, et al. Genetics of follicular lymphoma transformation. Cell Rep 2014;6:130-40.
10. Okosun J, Bodor C, Wang J, Araf S, Yang CY, Pan C, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 2014;46:176-81.
11. Hayslip J, Montero A. Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. Mol Cancer 2006;5:44.
12. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, et al. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol 2013;190:6681-93.
13. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010;463:318-25.
14. Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ,Castillo-Martin M, Zheng T, et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 2014;25:638-51.
15. Lefebvre C, Rajbhandari P, Alvarez MJ, Bandaru P, Lim WK, Sato M, et al. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol Syst Biol 2010;6: 377.
16. Lossos IS, Alizadeh AA, Diehn M, Warnke R, Thorstenson Y, Oefner PJ, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U S A 2002;99:8886-91.
17. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet 2005;37:382-90.
18. Chen JC, Alvarez MJ, Talos F, Dhruv H, Rieckhof GE, Iyer A, et al. Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. Cell 2014;159:402-14.
19. Hedvat CV, Hegde A, Chaganti RS, Chen B, Qin J, Filippa DA, et al. Application of tissuemicroarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 2002;33:968-74.
20. Davies AJ, Rosenwald A, Wright G, Lee A, Last KW, Weisenburger DD, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 2007;136: 286-93.
21. Basso K, Saito M, Sumazin P, Margolin AA, Wang K, Lim WK, et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood 2010;115:975-84.
22. Subramanian A, Tamayo P, Mootha VK,Mukherjee S, Ebert BL,Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
23. Lim WK, Lyashenko E, Califano A. Master regulators used as breast cancer metastasis classifiers. Pac Symp Biocomput 2009;14:504-15.
24. Siminovitch KA, Jensen JP, Epstein AL, Korsmeyer SJ. Immunoglobulin gene rearrangements and expression in diffuse histiocytic lymphomas reveal cellular lineage, molecular defects, and sites of chromosomal translocation. Blood 1986;67:391-7.
25. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985;41:899-906.
26. Knuutila S, Klefstrom J, Szymanska J, Lakkala T, Peltomaki P, Eray M, et al. Two novel human B-cell lymphoma lines of lymphatic follicle origin: cytogenetic, molecular genetic and histopathological characterisation. Eur J Haematol 1994;52:65-72.
27. Lombardi L, Newcomb EW, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. Cell 1987;49:161-70.
28. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
29. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-35.
30. Mani KM, Lefebvre C, Wang K, Lim WK, Basso K, Dalla-Favera R, et al. A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas. Mol Syst Biol 2008;4:169.
31. Woo HJ, Shimoni Y, Yang SW, Subramaniam P, Iyer A, Nicoletti P. Elucidating compound mechanism of action by network dysregulation analysis in perturbed cells. Cell 2015;162:441-51.
32. Weinstein IB. Cancer. Addiction to oncogenes-The Achilles heal of cancer. Science 2002;297:63-4.
33. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-37.
34. Yano T, Jaffe ES, Longo DL, Raffeld M. MYC rearrangements in histologically progressed follicular lymphomas. Blood 1992;80:758-67.
35. Uddin S, Hussain AR, Ahmed M, Siddiqui K, Al-Dayel F, Bavi P, et al. Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma. Haematologica 2012;97:1092-100.
36. Chan JA, Olvera M, Lai R, Naing W, Rezk SA, Brynes RK. Immunohistochemical expression of the transcription factor DP-1 and its heterodimeric partner E2F-1 in non-Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 2002;10:322-6.
37. Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, et al. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 2006;134:145-56.
38. Shah SN, Resar LM. High mobility group A1 and cancer: potential biomarker and therapeutic target. Histol Histopathol 2012;27:567-79.
39. Shah SN, Kerr C, Cope L, Zambidis E, Liu C, Hillion J, et al. HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks. PLoS One 2012;7:e48533.
40. O'Connor DJ, Lam EW, Griffin S, Zhong S, Leighton LC, Burbidge SA, et al. Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO J 1995;14:6184-92.
41. Monaco SE, Angelastro JM, Szabolcs M, Greene LA. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer 2007;120:1883-90.
42. Bishop JF, Matthews JP, Young GA, Bradstock K, Lowenthal RM. Intensified induction chemotherapywith high dose cytarabine and etoposide for acute myeloid leukemia: a reviewand updated results of the Australian Leukemia Study Group. Leuk Lymphoma 1998;28:315-27.
43. McCarthy J, Gopal AK. Successful use of full-dose dexamethasone, highdose cytarabine, and cisplatin as part of initial therapy in non-hodgkin and hodgkin lymphoma with severe hepatic dysfunction. Clin Lymphoma Myeloma 2009;9:167-70.
44. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011;31:986-1000.
45. Soleymani Fard S, Jeddi TehraniM, Ardekani AM. Prostaglandin E2 induces growth inhibition, apoptosis and differentiation in T and B cell-derived acute lymphoblastic leukemia cell lines (CCRF-CEM and Nalm-6). Prostaglandins Leukot Essent Fatty Acids 2012;87:17-24.
46. Wolffenbuttel BH, Graal MB. New treatments for patients with type 2 diabetes mellitus. Postgrad Med J 1996;72:657-62.
47. Padilla J, Leung E, Phipps RP. Human B lymphocytes and B lymphomas express PPAR-gamma and are killed by PPAR-gamma agonists. Clin Immunol 2002;103:22-33.
48. Bordessa A, Colin-Cassin C, Grillier-Vuissoz I, Kuntz S, Mazerbourg S, Husson G, et al. Optimization of troglitazone derivatives as potent antiproliferative agents: towards more active and less toxic compounds. Eur J Med Chem 2014;83:129-40.
49. Ho YS, Wu CH, Chou HM, Wang YJ, Tseng H, Chen CH, et al. Molecular mechanisms of econazole-induced toxicity on human colon cancer cells: G0/G1 cell cycle arrest and caspase 8-independent apoptotic signaling pathways. Food Chem Toxicol 2005;43:1483-95.
50. Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 2008;133:1106-17.